On November 5, BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS recorded an Intraday Rise of 5.62% in Regular Trading, trading at $400.5851 with turnover of $74.3225 million.
The clearest catalyst was a same-day earnings and guidance update: the company reported third-quarter revenue growth and raised its full-year revenue outlook, reinforcing momentum already supported by an FDA priority review decision for a Brukinsa combination regimen.
The company said first-nine-month revenue reached RMB 34.993 billion, up 26.8% year over year, while net profit attributable to shareholders rose 431.8% to RMB 6.055 billion. It also said third-quarter revenue grew 34% year over year and lifted expected full-year revenue to RMB 46.3 billion-RMB 47.0 billion from RMB 44.9 billion-RMB 46.2 billion previously; revenue less operating cost and expenses is expected at RMB 8.4 billion-RMB 9.0 billion. Earlier in the day, it also disclosed that the FDA granted priority review to a supplemental application for Brukinsa plus rituximab in first-line adult mantle cell lymphoma, based on phase 3 data showing a 43% reduction in disease progression or death risk versus a standard chemoimmunotherapy regimen.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments